January – June 2022

Interim Report

alzinova

We will make it possible for Alzheimer's patients to live an independent and active life

Summary of the period January-June 2022

Highlights

Phase 1b study is ongoing according to plan
- Positive external safety review of the phase 1b study with recommendation to continue the study

Successful rights issue that was subscribed by 80%, the Company received SEK 34 million before costs

Alzinova established scaled-up manufacturing process for ALZ-101 ahead of phase two studies

Key figures from the period

Three months, April – June 2022

- Net sales amounted to 0 SEK (0 SEK).
- Result after financial items amounted to -3,299,600 SEK (-2,179,986 SEK).
- Earnings per share amounted to -0.10 SEK (-0.14 SEK).

Six months, January – June 2022

- Net sales amounted to 0 SEK (0 SEK).
- Result after financial items amounted to -5,581,756 SEK (-3,641,239 SEK).
- Earnings per share amounted to -0.17 SEK (-0.23 SEK).
- Equity ratio amounted to 96.5% (93.7%).

Result per share: The period's result divided by 32,419,034 shares as of 2022-06-30, including paid subscribed units ("BTU") for registered shares but not yet transferred to owners as of this date (15,775,724 shares as of 2021-06-30).
Equity ratio: Total equity divided by total capital.
Amounts in brackets: Corresponding period in previous year.
"the Company" or **"Alzinova"** refers to Alzinova AB with corporate identity number: 556861-8168.

Significant events during the second quarter

- In April, Alzinova's board decided on a preferential issue of units corresponding to SEK 42.5 million if fully subscribed. The issue proceeds will primarily be used to finance the completion of the phase 1b-study and extension of the study for the vaccine candidate ALZ-101 as well as to prepare for the phase 1b study of the antibody ALZ-201.
- The Company announced that an external review of the phase 1b study of the safety data shows positive results and the study for ALZ-101 therefore continues according to plan.
- In May, Alzinova published a prospectus due to the preferential issue of units.
- The Company called for an annual general meeting, which was held on May 18, 2022, and all proposals for decisions were adopted by the general meeting. The minutes for the meeting are available on the Company's website, www.alzinova.com.
- The Company announced continued preclinical development of the antibody candidate ALZ-201 which was part of the preparations for clinical studies.
- Alzinova published the results of the rights issue. Subscription rate of 80%, the Company received SEK 34 million before issue costs.
- Alzinova engaged Mangold Fondkommission as liquidity provider for the Company share.

Significant events after the end of the second quarter

- In July, Alzinova announced that it has successfully verified that the manufacturing process for vaccine doses of ALZ-101, the Company's vaccine candidate against Alzheimer's disease, can be scaled up to deliver the larger production volumes required for phase 2 clinical trials.
- The Company announced that the preferential issue of units was registered with the Swedish Companies Registration Office.
- The Company announced that 50% of the patients for the ongoing phase 1b study had been recruited to the study. The goal is for all patients to be recruited in 2022.

A word from the CEO

During an eventful quarter, Alzinova has continued to build a stable foundation for the further development of the Company's pharmaceutical portfolio, which has strong potential to be "best-in-class". Recruitment to the Company's phase 1b study is proceeding according to plan with the goal of recruiting all patients to the study in 2022.

ALZ-101 – Half of the patients recruited in the phase 1b study

During the summer, we reached the important milestone of having recruited half of the patients in the ongoing phase 1b clinical study. We are well on our way to our goal of recruiting all patients to the study by the end of 2022.

The study therefore continues according to plan and in April the first review of blinded safety data from the study was carried out. The external expert group recommended continuing the study, which was an important step in the development of ALZ-101. The expert group now conducts regular reviews to follow up the safety data accumulated during the conduct of the study.

The vaccine can be scaled up for larger production volumes

Preparations for clinical phase 2 studies are progressing according to plan, and it is encouraging that we have now ensured that the manufacturing process can produce larger volumes of our vaccine candidate ALZ-101. We have already optimized the manufacturing of the active ingredient in the vaccine and have now in the second quarter also validated that the manufacturing process for the drug can be scaled up for larger production volumes. These are important steps for the long-term goal of cost-effectively produce and offer a vaccine against Alzheimer on the global market. In addition, these will be important elements that potential partners review and contributes also to increased interest in partnership.

ALZ-201 – being developed to enter into clinical phase

During the second quarter, work began on developing a stable manufacturing process for large-scale production of the antibody ALZ-201 in preparation for upcoming clinical studies. Unlike other antibodies that are being developed today, this antibody is more specific and targeted against the toxic peptides that break down brain cells, so-called oligomers. Protecting the brain cells from the toxic action of the oligomers could result in a treatment with better efficacy and a more favourable safety profile. We see several possible uses for ALZ-201. It can be further developed both as a stand-alone treatment against Alzheimer, and as a complement to the vaccine ALZ-101 for patients who, for various reasons, need higher levels of antibodies.

Strengthened financial position and more attractive for partnerships

Financially, we strengthened our position and the possibilities to make our drug candidates more attractive for partnerships, through the recent rights issue. The new capital ensures the financing of the vaccine candidate ALZ-101, the completion of the clinical study, strategic marketing and IP, as well as preparations for the next clinical development phase - phase 2. For the antibody ALZ-201, the preclinical development work is funded, thereby preparing the antibody so that we can take also this drug candidate into the clinic.

We have ongoing dialogues with potential partners who are established pharmaceutical companies. These companies follow our development projects with great interest and look forward to the data that we are currently generating in the clinical study, which will strengthen both the clinical and commercial interest in the vaccine ALZ-101 and the antibody ALZ-201.

We are very grateful for the interest in our rights issue and I would like to thank both our existing shareholders for their trust and all interested parties who have chosen to invest in Alzinova. We now look forward to completing recruitment for the phase 1b study, continuing dialogues with potential partners and preparing for phase 2. If we achieve the results we expect to achieve with our clinical program, Alzinova and its shareholders face a very exciting future.

Kristina Torfgård,
Alzinova AB

> We are now looking forward to completing the recruitment for the phase 1b study, continuing the dialogues with potential partners and preparing for phase 2.



About Alzinova

Alzinova AB is a Swedish biopharmaceutical Company specializing in the treatment of Alzheimer's disease. The Company's proprietary AβCC peptide technology™ enables the development of disease-modifying treatments that, with high precision, target the toxic accumulations of the peptide amyloid beta, so-called oligomers, which are central to the onset and progression of the disease. Using this technology, we can develop effective treatments which at the same time have a favourable safety profile with a lower risk of side effects. Promising preclinical results have been obtained following completion of a study on brain extracts from deceased Alzheimer's patients. The study confirms that Alzinova's unique method for specifically targeting and neutralizing toxic oligomers is effective.

Alzinova's focus is the development of a vaccine that specifically targets and neutralizes the toxic oligomers. The vaccine is developed as a long-acting drug for the treatment and prevention of Alzheimer's disease. The drug candidate ALZ-101 is in clinical development and a phase 1b study with Alzheimer's patients was initiated in the third quarter of 2021. Top-line data is expected to be presented in the second half of 2023.

Based on the same technology, the Company is also developing the antibody, ALZ-201, which is currently in the preclinical development phase. The project portfolio for the development of disease-modifying treatments is broadened by the Company by preparing the antibody so that it can also be taken into the clinical phase. Alzinova was founded by researchers who worked at the MIVAC research center at the University of Gothenburg and by GU Ventures AB.

Alzinova's unique solution

- Targeted treatment that specifically targets and neutralizes the toxic peptides (so-called oligomers) that are central to the onset and development of Alzheimer's disease
- Vaccine that stimulates the body to produce its own antibodies against oligomers
- Antibody that neutralizes the peptides and can be used as is or as a complement to the vaccine
- Fast, effective and uncomplicated vaccination without long and expensive hospital stays
- Specific treatment that is likely to have a good efficacy and reduces the risk of serious side effects
- Can start treatment early in the disease to prevent progression

Other actors

- Are developing treatments that target larger accumulations of amyloid-beta, so-called plaques in the brain, which are believed to contain both toxic and harmless protein.
- Non-specific treatments which does not specifically target and neutralize the toxic oligomers
- Often complicated drug treatments that require expensive hospital care
- Targeting plaque is unlikely to be sufficiently effective and may result in serious side effects





About Alzheimer

In Alzheimer's disease, the nerve cells in the brain are damaged by abnormal protein deposits that mainly consist of amyloid-beta 42 (Aβ42), a type of small protein that also occurs in a healthy brain. When the Aβ42 molecule clumps together, stable accumulations are formed in the brain, plaques, but also so-called oligomers.

Oligomers differ structurally from the plaque and, unlike the plaque, are highly toxic to brain cells. They damage important functions that make the contact surfaces between the nerve cells, the synapses, stop working normally. Synapses are the places in the brain where electrical and chemical signals are transmitted from one nerve cell to another, and their function is critical to our ability to remember, react, think and act. Eventually the nerve cell dies.

The disease first affects the parts of the brain that handle short-term memory, but eventually the disease spreads over the entire brain and the patient finds it increasingly difficult to carry out daily tasks. In the end, the patient cannot manage on their own, but requires care and continuous review.

Alzheimer's is a disease that basically anyone can get, and which is strongly age-dependent. Over 95% of all cases affect those over 65, and in these cases there is not a strong genetic component driving the disease. The disease then increases sharply in prevalence in the 75-80 age range. At age 95, the prevalence is perhaps as high as 50%. As the average life expectancy is increasing, this will entail large patient groups in the near future.

Business model

Alzinova's business model is to bring projects into clinical development with the aim of demonstrating that the drug candidates are safe and well tolerated as well as determining proof-of-concept, i.e. support for efficacy in patients with Alzheimer's. Based on clinical data, the Company intends to identify one or several strategic partners that can acquire projects for further development. This can be done through out-licensing with a partnership where the Company jointly with the partner brings the drug to the market, or through a complete acquisition of the drug candidate for further development.

Out-licensing
A common option for development companies such as Alzinova is to out-license projects to one or more major pharmaceutical players. Either these can get exclusivity in a limited market and you agree with several partners to cover the market globally, or you have a global partner who takes the drug to the entire market. A typical arrangement for out-licensing is initial compensation and then future instalments linked to pre-defined milestones during further development, the regulatory process and commercialization with high revenues linked to future drug sales.

The Company has so far taken several important steps towards out-licensing. It has secured a scalable manufacturing process for ALZ-101, which facilitates the company moving to phase 2 so that a partner can quickly start. With positive results in the Company's pharmaceutical projects ALZ-101 and ALZ-201, there are several options. One is to out-license the vaccine ALZ-101 when the phase 1b study is complete, and another option is to take it through to phase 2 and then out-license it to a partner. For the antibody ALZ-201, this could be out-licensed already during the preclinical phase, alternatively after phase 1b studies. The Company's focus going forward is precisely on business development with several active ongoing dialogues in parallel with clinical development of the project portfolio.

Market

Every year, around 10 million people globally fall victim to dementia; Alzheimer's disease accounts for approximately 60-70 percent of that number. The incurable dementia disorders represent a growing problem as life expectancy increases. It is estimated that dementia afflicts around 55 million patients worldwide The number is projected to rise to more than 130 million people in 2050. It is estimated that more than 30 million people around the world are suffering from Alzheimer's disease today, and the number is set to triple by 2050[1].

The cost to society of the disease is estimated today to be approximately USD 1.3 trillion annually. The annual pharmaceutical expenditure related to just symptom-relief drugs for Alzheimer's disease amounts to approximately USD 6 billion. Although the first drug for disease modification was recently approved in the USA, there is still a very long way to go to fully treat and prevent the progression of Alzheimer's disease.

The sales and revenue potential of a new effective drug is therefore substantial even if it only obtains an initially limited market share. The reason that the initial estimated sales revenues are relatively low compared to other therapeutic areas is that there are currently no good medical alternatives. If effective treatment alternatives were to come to the market, for example Alzinova's pharmaceuticals, the Company estimates that annual sales could multiply. According to Global Data, the annual sales volume of disease modifying therapies for Alzheimer's disease in the major markets US, Germany, France, UK, Italy, Spain, Japan, China and India will amount to USD 13 billion in 2028.

[1] World Health Organization (WHO) – Alzheimer's facts, september 2021.


Every 5 seconds someone is affected by Alzheimer's disease

Financial information

Corporate structure and shareholding
Alzinova has no subsidiaries and is not part of any group. Neither does the Company hold any shares.

Financial development
During the period, the Company has continued to invest in the development of the vaccine ALZ-101 and started development for clinical studies of the antibody ALZ-201, with the goal of treating and also preventing the progression of Alzheimer's disease.

The Company's other external costs during the period decreased by approximately SEK 2.7 million compared to the previous quarter and amounted to SEK 4.9 million during the period. The majority of external costs, SEK 3.9 million, are costs for research and development that have been capitalized in the balance sheet. The decrease compared to the previous quarter is mainly due to the higher costs for the optimization and scale-up of the ALZ-101 manufacturing process carried out in the previous period. Other external costs that have not been capitalized have during the period increased by SEK 1.1 million compared to the previous period and are mainly due to costs in connection with the rights issue carried out in the period.

Personnel costs of SEK 1.6 million are SEK 0.1 million lower than the previous quarter and according to budget.

At the end of the reporting period (30 June 2022), the Company's equity amounted to SEK 113 million with an equity ratio of 96.5% (SEK 92 million and 93.7% respectively as per 30 June 2021), and the cash balance amounted to approximately SEK 44 million (SEK 41 million as per 30 June 2021).

Risk factors
Alzinova maintains procedures to continuously identify and manage risk factors. A detailed assessment of the Company's uncertainty factors was included in the Annual Report 2021, as well as in the Prospectus for Alzinova Rights Issue 2022.

Auditor's review
This report has not been reviewed by the Company's auditors.

Policies for the preparation of the interim financial report
The interim financial report is prepared in accordance with the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3).

The Board of Directors and the Chief Executive Officer hereby confirm that this interim report provides a true and fair view of the Company's operations, financial position and earnings, and describes significant risks and uncertain factors the Company is facing.

Mölndal, August 25th 2022
Alzinova AB

Income statement

SEK	Apr -Jun 2022 3 months	Apr -Jun 2021 3 months	Jan -Jun 2022 6 months	Jan -Jun 2021 6 months	Jan -Dec 2021 12 months
Net sales	-	-	-	-	-
Own work capitalized	3,067,864	5,272,350	9,990,835	12,232,254	17,321,738
	3,067,864	**5,272,350**	**9,990,835**	**12,232,254**	**17,321,738**
Operating expenses					
Other external expenses	-4,875,666	-6,232,886	-12,446,857	-13,481,545	-19,025,906
Personnel expenses	-1,489,758	-1,194,930	-3,117,027	-2,367,428	-5,815,184
Operating result	**-3,297,560**	**-2,155,466**	**-5,573,049**	**-3,616,719**	**-7,519,352**
Result from financial items					
Interest expenses	-2,040	-24,520	-8,707	-24,520	-32,654
Result after financial items	**-3,299,600**	**-2,179,986**	**-5,581,756**	**-3,641,239**	**-7,552,006**
Result before tax	**-3,299,600**	**-2,179,986**	**-5,581,756**	**-3,641,239**	**-7,552,006**
Result for the period	**-3,299,600**	**-2,179,986**	**-5,581,756**	**-3,641,239**	**-7,552,006**

Balance sheet

SEK	30 June 2022	30 June 2021	31 December 2021
ASSETS			
Fixed assets			
Intangible assets			
Capitalized expenditure for development work	70,006,062	54,925,743	60,015,227
Patent	1,632,086	1,632,086	1,632,086
	71,638,148	**56,557,829**	**61,647,313**
Total fixed assets	**71,638,148**	**56,557,829**	**61,647,313**
Current assets			
Short term receivables			
Tax receivables	138,604	87,944	129,296
Other receivables	829,826	611,209	575,385
Prepaid expenses and accrued income	545,610	263,817	503,861
	1,514,040	**962,970**	**1,208,542**
Cash and cash receivables	**44,060,070**	**41,108,851**	**28,835,537**
Total current assets	**45,574,110**	**42,071,821**	**30,044,079**
TOTAL ASSETS	**117,212,258**	**98,629,650**	**91,691,392**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	8,526,206	4,149,015	4,149,015
Fund for development costs	67,937,216	52,856,902	57,946,386
	76,463,422	**57,005,917**	**62,095,401**
Unrestricted equity			
Share premium	144,752,332	118,872,676	118,872,676
Retained result	-102,487,148	-79,854,828	-84,944,312
Results for the year/period	-5,581,756	-3,641,239	-7,552,006
	36,683,428	**35,376,609**	**26,376,358**
Total equity	**113,146,850**	**92,382,526**	**88,471,759**
Long term liabilities			
Other long term liabilities	800,000	800,000	800,000
	800,000	**800,000**	**800,000**
Short term liabilities			
Accounts payable	1,433,988	3,707,083	792,374
Other current liabilities	575,416	555,015	1,143,281
Accrued expenses and prepaid income	1,256,004	1,185,026	483,978
	3,265,408	**5,447,124**	**2,419,633**
TOTAL EQUITY AND LIABILITIES	**117,212,258**	**98,629,650**	**91,691,392**

Change in equity, condensed

Jan - jun 2022 6 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the year	**4,149,015**	**57,946,386**	**118,872,676**	**-92,496,318**	**88,471,759**
Rights issue	4,377,191		32,482,459		36,859,650
Transaction cost rights issue			-6,602,803		-6,602,803
Transfer within capital		9,990,830		-9,990,830	0
Net result for the period				-5,581,756	-5,581,756
At the end of the period	**8,526,206**	**67,937,216**	**144,752,332**	**-108,068,904**	**113,146,850**

Jan - Jun 2021 6 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the year	**4,149,015**	**40,624,648**	**118,872,676**	**-67,622,574**	**96,023,765**
Transfer within capital		-5,581,756		5,581,756	0
Net result for the period				-3,641,239	-3,641,239
At the end of the period	**4,149,015**	**35,042,892**	**118,872,676**	**-65,682,057**	**92,382,526**

Jan - Dec 2021 12 months	Share Capital	Fund for development costs	Share premium	Retained result incl. result for the year	Total equity
At the beginning of the year	**4,149,015**	**40,624,648**	**118,872,676**	**-67,622,574**	**96,023,765**
Transfer within capital		17,321,738		-17,321,738	0
Net result for the period				-7,552,006	-7,552,006
At the end of the period	**4,149,015**	**57,946,386**	**118,872,676**	**-92,496,318**	**88,471,759**

Cash flow statement, condensed

SEK	Apr -Jun 2022 3 months	Apr -Jun 2021 3 months	Jan -Jun 2022 6 months	Jan -Jun 2021 6 months	Jan -Dec 2021 12 months
Operating activities					
Result after financial items	-3,299,600	-2,179,986	-5,581,756	-3,641,239	-7,552,006
Adjustments for items not included in cash flow	-	-	-	-	-
Cash flow from operating activities before change in working capital	**-3,299,600**	**-2,179,986**	**-5,581,756**	**-3,641,239**	**-7,552,006**
Cash flow from change in working capital					
Increase (-)/Decrease (+) in operating receivables	307,800	-661,040	-305,498	-449,927	-695,499
Increase (+)/Decrease (-) in operating liabilities	-4,257,431	-204,243	845,775	1,455,230	-1,572,261
Cash flow from operating activities	**-7,249,231**	**-3,045,269**	**-5,041,479**	**-2,635,936**	**-9,819,766**
Investing activities					
Acquisition of intangible fixed assets	-3,067,864	-5,272,350	-9,990,835	-12,232,254	-17,321,738
Cash flow from investing activities	**-3,067,864**	**-5,272,350**	**-9,990,835**	**-12,232,254**	**-17,321,738**
Financing activities					
Share issue	34,039,983	-	36,859,650	-	-
Transaction costs share issue	-6,439,320	-	-6,602,803	-	-
Cash flow from financing activities	**27,600,663**	**0**	**30,256,847**	**0**	**0**
Cash flow for the period	**17,283,568**	**-8,317,619**	**15,224,533**	**-14,868,190**	**-27,141,504**
Cash and cash equivalents at the beginning of the period	**26,776,502**	**49,426,470**	**28,835,537**	**55,977,041**	**55,977,041**
Cash and cash equivalents at the end of the period	**44,060,070**	**41,108,851**	**44,060,070**	**41,108,851**	**28,835,537**

The share

Alzinova's share was listed on the Spotlight Stock Market on November 25, 2015. As of March 11, 2019, the Company is listed on the Nasdaq First North Growth Market in Stockholm. There is one class of shares in the Company. The share entitles to one (1) vote per share. Each share carries an equal right to a share in the Company's assets and results. As of June 30, the number of shares in Alzinova amounted to 32,419,034 after a further 16,209,515 shares, from the rights issue carried out in the period, were registered with the Swedish Companies Registration Office on the same date. However, paid subscription units (BTU) in the issue had not yet been converted into shares as of this date, but this only happened at the beginning of July. The list of owners below therefore reflects the distribution of registered shares as of 30 June 2022.

Largest owners per 30 June 2022*

Shareholder	No. of shares	Capital %
Försäkrings AB Avanza Pension	1,762,513	10.87%
Maida Vale Capital AB	1,734,332	10.70%
Nordnet Pensionsförsäkring AB	677,792	4.18%
MIVAC Development AB	531,312	3.28%
Ola Hermansson med bolag	400,000	2.47%
Sara Gjertz	323,784	2.00%
Ålandsbanken, för ägare	311,170	1.92%
Patrik Ahlvin	300,000	1.85%
Özlem Erdogdu Gül	254,154	1.57%
Jan Löngårdh	200,000	1.23%
Total 10 largest shareholders	**6,495,057**	**40.07%**
Total other shareholders	9,714,462	59.93%
Total all shareholders	**16,209,519**	**100.00%**

*) Excluding BTUs from the latest issue, when as of 2022-06-30 the corresponding amount of shares were not registered for the owners.

Share-based incentive programs

The Company's CEO and other senior executives as well as parts of the board, through a long-term incentive program, hold a total of 159,165 warrants of series 2020/2023, which entitle them to subscribe for an equal number of shares during the period June 1 - July 31, 2023.

If the warrants are fully exercised, this corresponded at the time of issue, a dilution of the number of shares and votes in the Company of approximately 2%, and after rights issue carried out during the current year, it corresponds to a dilution of approximately 0.5%.

Rights issue

In 2020, the Company carried out a rights issue together with a directed issue with connected warrants of the series TO2 2020/2022. A total of 867,590 warrants were exercised during January-February 2022, which increased the number of shares in the Company by 443,795 shares and provided the Company with approximately SEK 2.8 million in capital before issue costs. For more information, refer to the interim report January-March 2022.

Furthermore, during the reporting period, the Company carried out a rights issue with connected warrants of the series TO3. The issue, which was completed in June 2022 and was secured to 80%, provided the Company with approximately SEK 34.0 million before issue costs. In the event of full exercise of warrants of series TO3 that expire in April 2023, the Company can receive an additional capital injection of up to approximately SEK 40.8 million before costs.

The Company's shares were increased by 16,209,515 shares to a total of 32,419,034 shares and the share capital increased to a total of SEK 8,526,206. For existing shareholders who did not participate in the rights issue, the dilution amounts to approximately 50%. Furthermore, upon full exercise of warrants of series TO3, the number of shares in the Company may increase by an additional 12,967,612 shares, corresponding to a dilution of approximately 28% of the total number of shares in the Company.


A
L R
P
A
L R
P
A
L R

Financial calendar

Interim report 1, 2022	19 April 202
Interim report 2, 2022	25 August 2022
Interim report 3, 2022	27 October 2022
Year end report, 2022	23 February 2023

Financial reports are available on the Company's website www.alzinova.com from the day they are made public

For further information, please contact:

Kristina Torfgård, CEO, kristina.torfgard@alzinova.com, telephone +46 708 467975
Håkan Skogström, CFO, hakan.skogstrom@alzinova.com, telephone +46 705 850859
or mail directly to info@alzinova.com

Glossary, definitions and abbreviations

Amyloid-beta	A peptide (part of a protein) produced by the body that can aggregate in the brain and cause Alzheimer's disease
Biomarker	A measurable indicator of a disease
Clinical studies	A study evaluating a medicine, conducted in humans
Disease-modifying treatment	Treatment that targets the underlying cause of the disease
IP	Intellectual Property, eg patents
Monoclonal antibody	A type of antibody produced by a single clone of cells
Neurotoxic	Dangerous or poisonous to the brain
Oligomers	Proteins or peptides, clumped together, used to designate soluble peptide clumps
Peptide	Part of a protein (a small chain of amino acids too small to be classified)
Plaque	Local accumulation of clumped insoluble protein, in Alzheimer's mainly consisting of the peptide Abeta42

Investment highlights

- Alzinova's goal is to enable Alzheimer's patients to live an independent and active life.
- Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer's disease. The vaccine is in clinical development with a phase 1b study in Alzheimer's patients.
- Based on the same technology, Alzinova is also developing a monoclonal antibody, ALZ-201, as a complementary treatment to fight Alzheimer's disease.
- The data show that the unique specificity of Alzinova's vaccine (ALZ-101) and the monoclonal antibody (ALZ-201) provides "best-in-class" potential.
- Preparatory activities are underway for the next clinical development phase, making Alzinova's candidates more attractive for strategic partnership.

Alzinova AB (publ) (corporate identity number 556861-8168)
AstraZeneca BioVentureHub
Pepparedsleden 1
SE-431 83 Mölndal
Sverige

alzinova